SmileDirectClub Inc Class A
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SDCCQ research report →
Price Chart
About the company
SmileDirectClub, Inc. , an oral care company, offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a customer's dentist or orthodontist, and facilitating remote clinical monitoring through a network of orthodontists and general dentists through its proprietary teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, France, Spain, and Austria.
- CEO
- David Katzman
- IPO
- 2019
- Employees
- 2,700
- HQ
- Nashville, TN, US
Get TickerSpark's AI analysis on SDCCQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.40K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -4.18
- Div Yield
- 0.00%
- Gross Margin
- 69.65%
- Op Margin
- -55.68%
- Net Margin
- -18.35%
- ROE
- -61.09%
- ROIC
- -53.74%
Latest fiscal year · YoY change
- Revenue
- $470.74M-26.2%
- Gross Profit
- $327.85M-21.4%
- Op Income
- $-262,113,000
- Net Income
- $-86,404,000+15.7%
- EPS
- $-0.71+18.4%
- OCF Growth
- -11.8%
- FCF Growth
- +15.3%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 7.27
- RSI (14)
- 48
- Avg Volume
- 2.95K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
SmileDirectClub said Q2 results were down on revenue but improved on profitability and cash flow, and management raised full-year sales guidance as SmileMaker and CarePlus begin rolling out.· August 9, 2023
- Q2 revenue was $102 million, down 19% year over year and 15% sequentially, but adjusted EBITDA and free cash flow both improved by $10 million and $8 million versus last year.
- Gross margin was 71.6%, down from 72.5% in Q1, while marketing and selling expense fell to $50 million from $71 million a year ago.
- SmileMaker launched in the U.S. on a limited basis and was in the top 10 of Apple’s medical category; management said it is lowering cost per lead and could boost referrals through sharing.
- CarePlus, priced at $3,900, is being rolled out across U.S. SmileShop locations this month, with pilot results showing a meaningful take rate from existing customers.
- Full-year guidance was raised to $425 million-$475 million of revenue, 73%-76% gross margin, and negative $40 million to negative $10 million of adjusted EBITDA; management still expects positive adjusted EBITDA in Q3 and positive free cash flow in Q4.
Revenue for Q2 2023 was $102 million, down 19% year over year and 15% sequentially. Gross margin was 71.6%, down from 72.5% in Q1. Adjusted EBITDA was negative $14 million, an improvement of $10 million versus Q2 2022, and free cash flow was negative $28 million, an $8 million improvement year over year. Net loss was $54 million, improved by $11 million year over year. For the full year 2023, the company now expects revenue of $425 million-$475 million, gross margin of 73%-76%, adjusted EBITDA of negative $40 million to negative $10 million, CapEx of $30 million-$35 million, and one-time reorganization costs of $12 million-$15 million. Management said it still expects positive adjusted EBITDA in Q3 2023 and positive free cash flow in Q4 2023.
David Katzman framed the quarter around two strategic initiatives: SmileMaker, the mobile scanning app, and CarePlus, the premium $3,900 offering. He emphasized that both are now moving from pilot to rollout and can improve efficiency, referral sharing, and upsell opportunities through SmileShops and partner network locations. His tone was cautiously optimistic, but he repeatedly noted the difficult macro backdrop and the need for disciplined cost management and balance sheet work.
Troy Crawford highlighted that the cost structure continues to improve, with marketing and selling expense down to $50 million from $71 million a year ago and G&A down to $60 million from $72 million a year ago. He said gross margin was 71.6% and explained that the quarter’s adjusted EBITDA of negative $14 million benefited from restructuring and lower spending even as revenue fell to $102 million. He also noted $58 million in cash and cash equivalents, $179 million in net accounts receivable, $137 million drawn on the $255 million HPS debt facility, and negative free cash flow of $28 million, while pointing to a $10 million founder revolving credit agreement as a bridge for liquidity.
Analysts focused on how much of the second-half guidance is coming from SmileMaker and CarePlus, whether the new channels will cannibalize the legacy business, and what assumptions drive the step-up to the full-year range. Management said it is too early to break out the contribution by initiative because customers may start in one channel and convert through another, but they expect higher ASPs and more efficient conversion as the new offerings scale. Questions also centered on liquidity and the ABL/founding financing; management said the $10 million founder line is meant as a bridge, that they are exploring expansion of the ABL and other financing options, and that the Align litigation is not yet final and remains under appeal/vacatur efforts.
The bullish case from the call is that SmileMaker and CarePlus are starting to show operational traction: the app is getting download momentum, lowering cost per lead, and CarePlus is generating take rates in pilot SmileShops. Management also pointed to improving unit economics, record ASPs, lower marketing spend, and a fourth straight quarter of year-over-year adjusted EBITDA improvement.
The main bear case is that revenue remains under pressure from macro weakness, with Q2 sales down 19% year over year and management still expecting a tough consumer environment. Liquidity is also a concern: cash was $58 million, free cash flow was negative $28 million in the quarter, the ABL is constrained by receivables, and management is still working on balance sheet restructuring while facing ongoing litigation risk tied to Align.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.7%
- Shares Outstanding
- 133.98M
- Float Shares
- 133.65M
of shares held by institutions
1 13F filers
Our SDCCQ coverage
Recent articles, reports, and earnings notes.
No research on SDCCQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SDCCQ report →U.S. Dental Chains Market Forecasts 2024-2028, with Profiles of American Family Dentistry, Familia Dental, ForwardDental, OnSite Health, Smile Brands, SmileDirectClub, Western Dental Services & More
globenewswire.com · Jan 16
Sonrava Health Invites SmileDirectClub Patients to Enjoy Significant Savings While Completing Their Orthodontic Alignments with Specially Trained Dentists and Orthodontists
businesswire.com · Jan 2
Warning Signs: 3 Companies That Might Not Survive 2024
investorplace.com · Dec 19
SmileDirectClub customers are fuming after the company shut down — and left them with unfinished treatments and unpaid bills
businessinsider.com · Dec 12
SmileDirectClub ceases operations after restructuring effort fails
foxbusiness.com · Dec 11
SmileDirectClub winds down operations — but customers are told to keep paying
marketwatch.com · Dec 8
SmileDirectClub (SDCCQ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
zacks.com · Oct 30
Buyouts and Beyond: 7 Stocks Whose Only Hope Is Acquisition
investorplace.com · Oct 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.